Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
1.980
-0.110 (-5.26%)
May 13, 2025, 4:00 PM - Market closed
Immix Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 15.92 | 17.68 | 17.51 | 13.44 | 17.64 | 0.39 | Upgrade
|
| Cash & Short-Term Investments | 15.92 | 17.68 | 17.51 | 13.44 | 17.64 | 0.39 | Upgrade
|
| Cash Growth | -45.70% | 0.98% | 30.31% | -23.85% | 4411.66% | -46.72% | Upgrade
|
| Other Receivables | - | 1.97 | 1.17 | 0.26 | 0.03 | 0.13 | Upgrade
|
| Receivables | - | 1.97 | 1.17 | 0.26 | 0.03 | 0.13 | Upgrade
|
| Prepaid Expenses | 0.86 | 0.51 | 1.06 | 1.13 | 0.52 | 0.01 | Upgrade
|
| Other Current Assets | - | 0.03 | 0.04 | 0.08 | - | - | Upgrade
|
| Total Current Assets | 16.78 | 20.2 | 19.79 | 14.9 | 18.19 | 0.53 | Upgrade
|
| Property, Plant & Equipment | 3.09 | 2.73 | 0.05 | 0 | 0.01 | 0.01 | Upgrade
|
| Long-Term Deferred Charges | - | - | 0.09 | 0.01 | - | - | Upgrade
|
| Other Long-Term Assets | 0.02 | 0.02 | - | - | - | - | Upgrade
|
| Total Assets | 19.89 | 22.95 | 19.93 | 14.91 | 18.19 | 0.54 | Upgrade
|
| Accounts Payable | 9.24 | 5.39 | 1.43 | 0.14 | 0.14 | 0.25 | Upgrade
|
| Accrued Expenses | - | 3.23 | 2.29 | 1.13 | 0.01 | 0.34 | Upgrade
|
| Short-Term Debt | - | - | - | - | 0.05 | 0.05 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | - | 4.05 | Upgrade
|
| Current Portion of Leases | 0.07 | 0.07 | - | - | - | - | Upgrade
|
| Other Current Liabilities | - | - | - | - | - | 0.58 | Upgrade
|
| Total Current Liabilities | 9.31 | 8.69 | 3.72 | 1.27 | 0.2 | 5.27 | Upgrade
|
| Long-Term Leases | 0.99 | 1.01 | - | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0.48 | - | - | Upgrade
|
| Total Liabilities | 10.3 | 9.7 | 3.72 | 1.75 | 0.2 | 5.27 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 89.24 | 88.37 | 69.78 | 51.16 | 47.62 | 0.51 | Upgrade
|
| Retained Earnings | -79.57 | -75.02 | -53.41 | -37.99 | -29.76 | -5.37 | Upgrade
|
| Treasury Stock | -0.1 | -0.1 | -0.1 | -0.1 | - | - | Upgrade
|
| Comprehensive Income & Other | 0.02 | -0 | 0.13 | 0.09 | 0.13 | 0.13 | Upgrade
|
| Total Common Equity | 9.59 | 13.25 | 16.41 | 13.16 | 17.99 | -4.73 | Upgrade
|
| Minority Interest | - | - | -0.2 | - | - | - | Upgrade
|
| Shareholders' Equity | 9.59 | 13.25 | 16.2 | 13.16 | 17.99 | -4.73 | Upgrade
|
| Total Liabilities & Equity | 19.89 | 22.95 | 19.93 | 14.91 | 18.19 | 0.54 | Upgrade
|
| Total Debt | 1.06 | 1.07 | - | - | 0.05 | 4.1 | Upgrade
|
| Net Cash (Debt) | 14.86 | 16.61 | 17.51 | 13.44 | 17.59 | -3.71 | Upgrade
|
| Net Cash Growth | -47.35% | -5.16% | 30.31% | -23.63% | - | - | Upgrade
|
| Net Cash Per Share | 0.50 | 0.59 | 1.01 | 0.97 | 4.79 | -1.10 | Upgrade
|
| Filing Date Shares Outstanding | 27.88 | 27.72 | 26.4 | 13.9 | 13.86 | 3.38 | Upgrade
|
| Total Common Shares Outstanding | 27.85 | 27.54 | 19.92 | 13.89 | 13.23 | 3.38 | Upgrade
|
| Working Capital | 7.47 | 11.51 | 16.07 | 13.62 | 17.98 | -4.74 | Upgrade
|
| Book Value Per Share | 0.34 | 0.48 | 0.82 | 0.95 | 1.36 | -1.40 | Upgrade
|
| Tangible Book Value | 9.59 | 13.25 | 16.41 | 13.16 | 17.99 | -4.73 | Upgrade
|
| Tangible Book Value Per Share | 0.34 | 0.48 | 0.82 | 0.95 | 1.36 | -1.40 | Upgrade
|
| Machinery | - | 0.85 | 0.06 | - | - | - | Upgrade
|
| Construction In Progress | - | 0.94 | - | - | - | - | Upgrade
|
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.